Conference Call and Live Audio Webcast
Scheduled for Thursday, November 9, 2023, at 10:00 a.m. ET
Corporate Highlights
- Third quarter of 2023 GAAP net income was $4.5 million or $0.36 per diluted share, compared with GAAP net
income of $6.6 million or
$0.51 per diluted share, for the
third quarter of 2022
- Closed an approximately $33.0
million public offering of senior notes
- After quarter end, upsized existing credit facility to
$60.0 million with new bank partner
Woodforest National Bank
- Year-to-date Enteris has booked $2.7
million of CDMO projects and has approximately $5.0 million of proposals outstanding
- SWK repurchased 60,335 shares of common stock during the
quarter for a total cost of $1.0
million; year-to-date through November 6, 2023, SWK has purchased 361,593
shares for a total cost of $6.1
million
Finance Receivables Segment Update
- Third quarter of 2023 finance receivables segment adjusted
non-GAAP net income was $5.8 million,
compared with adjusted non-GAAP net income of $6.0 million for the third quarter of 2022
- As of September 30, 2023, gross
finance receivables were $234.9
million, a 10.3% increase from September 30, 2022
- After quarter end, closed a $20.0
million loan to Shield Therapeutics PLC as well as a
$6.0 million loan to Nicoya
Lifesciences, Inc.
- Third quarter of 2023 finance portfolio effective yield was
14.0%, a 30-basis-point decrease from September 30, 2022
- As of September 30, 2023, book
value per share was $22.19
- As of September 30, 2023,
non-GAAP tangible financing book value per share was $19.35. After adjusting for the effect of CECL
adoption, non-GAAP tangible financing book value per share
increased 6.2% year-over-year
DALLAS, Nov. 9, 2023
/PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or
the "Company"), a life science-focused specialty finance company
catering to small- and mid-sized commercial-stage companies, today
provided a business update and announced its financial and
operating results for the third quarter ended September 30, 2023.
"SWK generated healthy financial returns, improved our balance
sheet through the issuance of approximately $33.0 million of senior unsecured notes and a
$15.0 million upsizing of our credit
facility, and our Enteris subsidiary made progress to achieving
profitability. The finance segment generated $5.6 million of pre-tax net income and
$5.8 million of adjusted non-GAAP net
income. The portfolio generated a 14.0% effective yield, and gross
finance receivables increased slightly sequentially to $234.9 million, as a new $5.0 million loan to a privately held CDMO was
partially offset by principal repayments. After quarter end, we
closed two additional term loans, deploying $26.0 million of shareholder capital," stated
Jody Staggs, President and CEO of
SWK.
Mr. Staggs continued: "In 2023 Enteris has booked $2.7 million of CDMO projects and has proposals
outstanding on an additional $5.0
million of work. Enteris' third quarter revenue increased
72% to $0.3 million sequentially, and
we anticipate strong revenue growth in the fourth quarter driven by
referrals from our strategic partner. The increase in sequential
revenue and reduced cost structure led to a sequential improvement
in the third quarter operating loss. We continue to work with the
Enteris team to achieve profitability and maximize subsidiary
value."
"During the fourth quarter, we are focused on diligently
deploying our balance sheet capital, which currently totals more
than $60.0 million. We are also in
regular contact with our borrowers to ensure they acknowledge the
challenging economic and capital markets environment and are taking
appropriate steps to ensure their business can operate through a
more difficult period."
Third Quarter 2023 Financial Results
For the third quarter 2023, SWK reported total revenue of
$9.0 million, a 34.2% decrease
compared to $13.6 million for the
third quarter 2022. The $4.6 million
decrease in revenue for the three months ended September 30, 2023, consisted of a $4.7 million decrease in Pharmaceutical
Development segment revenue and a $0.1
million increase in Finance Receivables segment revenue. The
$4.7 million decrease in
Pharmaceutical Development segment revenue was primarily due to
$5.0 million of milestone revenue
related to Enteris' License Agreement with Cara received during the
three months ended September 30,
2022, and no similar milestone revenue was recognized during
the three months ended September 30,
2023. The $0.1 million
increase in Finance Receivables segment revenue was primarily the
result of an increase in reference rates.
Pre-tax net income for the three months ended September 30, 2023, was $4.1 million, compared to $8.6 million for the same period of the previous
year. The year-over-year decrease is primarily due to a
$4.6 million decrease in consolidated
revenue and a $2.0 million decrease
in unrealized losses on our warrant assets, equity securities and
foreign currency transactions, partially offset by a $2.4 million decrease in operating expenses in
both segments.
GAAP net income for the quarter ended September 30, 2023, decreased 32.4% to
$4.5 million, or $0.36 per diluted share, from $6.6 million, or $0.51 per diluted share, for the third quarter
2022.
For the third quarter 2023, non-GAAP adjusted net income was
$4.8 million, a 42.6% decrease from
$8.3 million for the third quarter
2022. Non-GAAP adjusted net income for the Finance Receivables
segment was $5.8 million, a 3.2%
decrease from $6.0 million for the
third quarter 2022.
During the twelve months ended September
30, 2023, there were $29.4
million of loan repayments and royalty paydowns, which were
partially offset by $41.1 million of
new and existing investment funding. As a result, income-producing
assets (defined as finance receivables and corporate debt
securities) totaled $235.0 million as
of September 30, 2023. This is a
10.3% increase compared with income-producing assets of
$213.1 million as of September 30, 2022. Total investment assets,
which include income-producing assets plus equity-linked
securities, totaled $236.3 million as
of September 30, 2023, compared to
September 30, 2022, total investment
assets of $222.2 million.
Book value per share was $22.19 as
of September 30, 2023, compared to
$21.62 as of September 30, 2022. Book value per share
increased 6.2% compared to September 30,
2022, after adjusting for the effect of adopting the current
expected credit losses methodology ("CECL"). Non-GAAP tangible
financing book value per share totaled $19.35. Non-GAAP tangible financing book value
per share increased 6.2% compared to $19.14
September 30, 2022, after adjusting for the effect of CECL
adoption. Management views non-GAAP tangible financing book value
per share as a relevant metric to value the Company's core finance
receivable business. Non-GAAP tangible financing book value per
share removes the value of the deferred tax assets and Enteris net
asset value.
Tables detailing SWK's financial performance for the third
quarter of 2023 are below.
Portfolio Status
During the third quarter, SWK closed a $5.0 million loan to a privately-held CDMO. After
quarter close, SWK closed two loans totaling $26.0 million. SWK is currently pursuing multiple
financing opportunities and anticipates closing additional
transactions over the next few months.
For the third quarter of 2023, the realized yield of the finance
receivables portfolio was 14.7%, versus 17.5% for the same period
in the previous year. The realized yield is inclusive of all fees,
including all realized unamortized fees, amendment fees, and
prepayment fees, and is calculated based on the simple average of
finance receivables at the beginning and end of the period. The
realized yield may differ from the effective yield due to actual
cash collections being greater or lesser than modeled.
As of September 30, 2023,
non-accrual finance receivables totaled $26.5 million. Of the total $26.5 million, $6.9
million consisted of royalty purchases, $10.4 million consisted of a non-accrual
financing to Flowonix Medical, which has now been reclassified as a
royalty, and $9.1 million consisted
of a loan to Trio Healthcare, which was placed on non-accrual
during the quarter. SWK is working with Trio to achieve a
resolution.
As of September 30, 2023, SWK had
$7.4 million of unfunded
commitments.
Total portfolio investment activity for the three months ended
September 30, 2023 and 2022 was as
follows (in thousands):
|
|
Three Months
Ended
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
Beginning
Portfolio
|
|
$
|
224,468
|
|
|
$
|
181,416
|
|
Early/loan
payoff
|
|
|
—
|
|
|
|
(8,543)
|
|
Provision for credit
losses
|
|
|
(223)
|
|
|
|
—
|
|
Interest
paid-in-kind
|
|
|
293
|
|
|
|
1,736
|
|
Investment in finance
receivables
|
|
|
5,000
|
|
|
|
46,400
|
|
Loan discount and fee
accretion
|
|
|
663
|
|
|
|
(294)
|
|
Remeasurement of
finance receivable
|
|
|
(690)
|
|
|
|
—
|
|
Net unrealized gain
(loss) on marketable investments and warrant assets
|
|
|
(162)
|
|
|
|
1,801
|
|
Principal payments
received on investments
|
|
|
(3,915)
|
|
|
|
(9)
|
|
Royalty
paydowns
|
|
|
(483)
|
|
|
|
(1,200)
|
|
Warrant and equity
investments, net of sales and cancellations
|
|
|
—
|
|
|
|
871
|
|
Ending
Portfolio
|
|
$
|
224,951
|
|
|
$
|
222,178
|
|
Adjusted Non-GAAP Net Income
The following table provides a reconciliation of SWK's reported
(GAAP) consolidated net income to SWK's adjusted consolidated net
income (Non-GAAP) for the three months ended September 30, 2023 and 2022. The table eliminates
provisions for (benefits from) income taxes, non-cash
mark-to-market changes on warrant assets, equity securities,
foreign currency gains and losses, amortization of Enteris'
intangible assets and any non-cash impact on the remeasurement of
contingent consideration.
(in
thousands)
|
|
Three Months
Ended
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
Net income
|
|
$
|
4,474
|
|
|
$
|
6,616
|
|
Add (subtract): Income
tax (benefit) expense
|
|
|
(386)
|
|
|
|
1,942
|
|
Add: Enteris
amortization expense
|
|
|
426
|
|
|
|
426
|
|
Add (subtract):
Unrealized net (gain) loss on warrant assets
|
|
|
162
|
|
|
|
(1,788)
|
|
Subtract: Unrealized
net gain on equity securities
|
|
|
—
|
|
|
|
(13)
|
|
Add: foreign currency
transaction loss
|
|
|
76
|
|
|
|
—
|
|
Add: Other one-time
expenses
|
|
|
—
|
|
|
|
(1,100)
|
|
Adjusted income before
income tax expense
|
|
|
4,752
|
|
|
|
8,283
|
|
Add (subtract): Income
tax (benefit) expense
|
|
|
—
|
|
|
|
—
|
|
Non-GAAP adjusted net
income
|
|
$
|
4,752
|
|
|
$
|
8,283
|
|
|
|
In the table above, management has deducted the following
non-cash items: (i) change in the fair-market value of equities and
warrants, as mark-to-market changes are non-cash, (ii) income
taxes, as the Company has substantial net operating losses to
offset against future income, (iii) amortization expense associated
with Enteris' intangible assets, and (iv) (gain) loss on
remeasurement of contingent consideration.
Finance Receivables Adjusted Non-GAAP Net Income
The following table provides a reconciliation of SWK's
consolidated adjusted income before provision for income tax
expense, listed in the table above, to the non-GAAP adjusted net
income for the Finance Receivable segment for the three months
ended September 30, 2023 and 2022.
The table eliminates Enteris' operating loss. The adjusted income
before income tax expense is derived in the table above and
eliminates income tax expense, non-cash mark-to-market changes on
warrant assets and equity securities.
(in
thousands)
|
|
Three Months
Ended
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
Non-GAAP adjusted net
income
|
|
$
|
4,752
|
|
|
$
|
8,283
|
|
Add (Subtract): Enteris
operating loss (income), excluding amortization expense and change
in fair value of contingent consideration
|
|
|
1,070
|
|
|
|
(2,270)
|
|
Adjusted Finance
Receivables segment income before income tax expense
|
|
$
|
5,822
|
|
|
$
|
6,013
|
|
Adjusted income tax
expense
|
|
|
—
|
|
|
|
—
|
|
Finance Receivables
segment adjusted non-GAAP net income
|
|
$
|
5,822
|
|
|
$
|
6,013
|
|
|
|
Non-GAAP Tangible Finance Book Value Per Share
The following table provides a reconciliation of SWK's GAAP book
value per share to its non-GAAP tangible finance book value per
share as of September 30, 2023 and
2022. The table eliminates the deferred tax assets, intangible
assets, goodwill, Enteris' property and equipment and
acquisition-related contingent consideration.
(in
thousands)
|
|
Three Months Ended
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
GAAP shareholders'
equity
|
|
$
|
277,565
|
|
|
$
|
277,446
|
|
Shares
outstanding
|
|
|
12,511
|
|
|
|
12,835
|
|
GAAP book value per
share
|
|
$
|
22.19
|
|
|
$
|
19.14
|
|
|
|
|
|
|
|
|
|
|
Subtract: Deferred tax
assets, net
|
|
|
26,090
|
|
|
|
17,350
|
|
Subtract: Intangible
assets, net
|
|
|
6,913
|
|
|
|
8,615
|
|
Subtract:
Goodwill
|
|
|
8,404
|
|
|
|
8,404
|
|
Subtract: Enteris
property and equipment, net
|
|
|
5,325
|
|
|
|
5,934
|
|
Add: Contingent
consideration payable
|
|
|
11,200
|
|
|
|
8,530
|
|
Non-GAAP tangible
finance book value
|
|
|
242,033
|
|
|
|
245,673
|
|
Shares
outstanding
|
|
|
12,511
|
|
|
|
12,835
|
|
Non-GAAP tangible
finance book value per share
|
|
$
|
19.35
|
|
|
$
|
19.14
|
|
|
Non-GAAP Financial Measures
This release includes non-GAAP adjusted net income, non-GAAP
finance receivable segment net income, and non-GAAP tangible
financing book value per share, which are metrics that are not
compliant with generally accepted accounting principles in
the United States (GAAP).
Non-GAAP adjusted net income is adjusted for certain items
including (i) changes in the fair-market value of public
equity-related assets and SWK's warrant assets as mark-to-market
changes are non-cash, (ii) income taxes as the Company has
substantial net operating losses to offset against future income,
(iii) changes in the fair-market value of contingent consideration
associated with the Enteris acquisition as these changes are
non-cash, and (iv) depreciation and amortization expenses,
primarily associated with the Enteris acquisition.
In addition to the adjustments noted above, non-GAAP finance
receivable segment net income also excludes Enteris' operating
losses.
Non-GAAP tangible financing book value per share excludes the
deferred tax asset, intangible assets, goodwill, Enteris' PP&E,
and contingent consideration associated with the Enteris
transaction.
These non-GAAP measures may not be directly comparable to
similar measures used by other companies in the Company's industry,
as other companies may define such measures differently. Management
believes that these measures are useful to investors and management
in understanding our ongoing operations and in analysis of ongoing
operating trends and provides useful additional information
relating to our operations and financial condition. The Company
encourages investors to carefully consider its results under GAAP,
as well as its supplemental non-GAAP information and the
reconciliation between these presentations, to more fully
understand its business. Non-GAAP financial results are reported in
addition to, and not as a substitute for, or superior to, financial
measures calculated in accordance with GAAP. Further, non-GAAP
financial measures, even if similarly titled, may not be calculated
in the same manner by all companies, and therefore should not be
compared.
Conference Call Information
SWK Holdings will host a conference call and live audio webcast
on Thursday, November 9, 2023 at 10:00
a.m. ET, to discuss its corporate and financial results for
the third quarter 2023.
Interested participants and investors may access the conference
call by dialing either:
(844) 378-6488 (U.S.)
(412) 317-1079 (International)
An audio webcast will be accessible via the Investors Events
& Presentations section of the SWK Holdings'
website: https://swkhold.investorroom.com/events. An archive
of the webcast will remain available for 90 days beginning at
approximately 11:00 a.m. ET, on
November 9, 2023.
About SWK Holdings Corporation
SWK Holdings Corporation is a life science focused specialty
finance company partnering with small- and mid-sized
commercial-stage healthcare companies. SWK provides non-dilutive
financing to fuel the development and commercialization of
lifesaving and life-enhancing medical technologies and products.
SWK's unique financing structures provide flexible financing
solutions at an attractive cost of capital to create long-term
value for all SWK stakeholders. SWK's solutions include structured
debt, traditional royalty monetization, synthetic royalty
transactions, and asset purchases typically ranging in size from
$5.0 million to $25.0 million. SWK also owns Enteris BioPharma, a
clinical development and manufacturing organization providing
development services to pharmaceutical partners as well as
innovative formulation solutions built around its proprietary oral
drug delivery technologies, the Peptelligence® platform. Additional
information on the life science finance market is available on the
Company's website at www.swkhold.com.
Safe Harbor For Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Statements including words such as "believes," "expects,"
"anticipates," "intends," "estimates," "plan," "will," "may," "look
forward," "intend," "guidance," "future" or similar expressions are
forward-looking statements. Because these statements reflect SWK's
current views, expectations and beliefs concerning future events,
these forward-looking statements involve risks and uncertainties.
Investors should note that many factors, as more fully described
under the caption "Risk Factors" and elsewhere in SWK's Form 10-K,
Form 10-Q and Form 8-K filings with the Securities and Exchange
Commission and as otherwise enumerated herein, could affect the
Company's future financial results and could cause actual results
to differ materially from those expressed in such forward-looking
statements. The forward-looking statements in this press release
are qualified by these risk factors. These are factors that,
individually or in the aggregate, could cause the Company's actual
results to differ materially from expected and historical results.
You should not place undue reliance on any forward-looking
statements, which speak only as of the date they are made. We
assume no obligation to publicly update any forward-looking
statements, whether as a result of new information, future
developments or otherwise.
SWK HOLDINGS
CORPORATION
|
UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(in thousands,
except share data)
|
|
|
|
September 30,
2023
|
|
|
December 31,
2022
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
31,034
|
|
|
$
|
6,156
|
|
Interest and accounts
receivable, net
|
|
|
4,411
|
|
|
|
3,094
|
|
Other current
assets
|
|
|
1,756
|
|
|
|
1,114
|
|
Total current
assets
|
|
|
37,201
|
|
|
|
10,364
|
|
|
|
|
|
|
|
|
|
|
Finance receivables,
net of allowance for credit losses of $11,327 and $11,846, as of
September 30, 2023 and December 31, 2022, respectively
|
|
|
223,604
|
|
|
|
236,555
|
|
Collateral on foreign
currency forward contract
|
|
|
2,750
|
|
|
|
2,750
|
|
Marketable
investments
|
|
|
50
|
|
|
|
76
|
|
Deferred tax assets,
net
|
|
|
26,090
|
|
|
|
24,480
|
|
Warrant
assets
|
|
|
1,297
|
|
|
|
1,220
|
|
Intangible assets,
net
|
|
|
6,913
|
|
|
|
8,190
|
|
Goodwill
|
|
|
8,404
|
|
|
|
8,404
|
|
Property and equipment,
net
|
|
|
5,479
|
|
|
|
5,840
|
|
Other non-current
assets
|
|
|
4,057
|
|
|
|
1,742
|
|
Total assets
|
|
$
|
315,845
|
|
|
$
|
299,621
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable and
accrued liabilities
|
|
|
2,768
|
|
|
|
3,902
|
|
Revolving credit
facility
|
|
|
22,000
|
|
|
|
2,445
|
|
Total current
liabilities
|
|
|
24,768
|
|
|
|
6,347
|
|
|
|
|
|
|
|
|
|
|
Contingent
consideration payable
|
|
|
11,200
|
|
|
|
11,200
|
|
Other non-current
liabilities
|
|
|
2,312
|
|
|
|
2,145
|
|
Total
liabilities
|
|
|
38,280
|
|
|
|
19,692
|
|
|
|
|
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001
par value; 5,000,000 shares authorized; no shares issued and
outstanding
|
|
|
—
|
|
|
|
—
|
|
Common stock, $0.001
par value; 250,000,000 shares authorized; 12,510,776 and 12,843,157
shares issued and outstanding as of September 30, 2023 and December
31, 2022, respectively
|
|
|
12
|
|
|
|
12
|
|
Additional paid-in
capital
|
|
|
4,425,198
|
|
|
|
4,430,922
|
|
Accumulated
deficit
|
|
|
(4,147,645)
|
|
|
|
(4,151,005)
|
|
Total stockholders'
equity
|
|
|
277,565
|
|
|
|
279,929
|
|
Total liabilities and
stockholders' equity
|
|
$
|
315,845
|
|
|
$
|
299,621
|
|
SWK HOLDINGS
CORPORATION
|
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF INCOME
|
(in thousands,
except per share data)
|
|
|
|
Three Months
Ended
September 30,
|
|
|
Nine Months
Ended
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
|
2023
|
|
|
2022
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance receivable
interest income, including fees
|
|
$
|
8,608
|
|
|
$
|
8,502
|
|
|
$
|
27,146
|
|
|
$
|
25,745
|
|
Pharmaceutical
development
|
|
|
315
|
|
|
|
5,111
|
|
|
|
616
|
|
|
|
5,461
|
|
Other
|
|
|
39
|
|
|
|
1
|
|
|
|
108
|
|
|
|
481
|
|
Total
revenues
|
|
|
8,962
|
|
|
|
13,614
|
|
|
|
27,870
|
|
|
|
31,687
|
|
Costs and
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for (benefit
from) credit losses
|
|
|
223
|
|
|
|
—
|
|
|
|
(459)
|
|
|
|
—
|
|
Interest
expense
|
|
|
176
|
|
|
|
82
|
|
|
|
721
|
|
|
|
242
|
|
Pharmaceutical
manufacturing, research and development expense
|
|
|
606
|
|
|
|
1,792
|
|
|
|
2,834
|
|
|
|
5,173
|
|
Depreciation and
amortization expense
|
|
|
652
|
|
|
|
634
|
|
|
|
1,937
|
|
|
|
1,964
|
|
General and
administrative expense
|
|
|
2,979
|
|
|
|
4,349
|
|
|
|
8,516
|
|
|
|
10,527
|
|
Income from
operations
|
|
|
4,326
|
|
|
|
6,757
|
|
|
|
14,321
|
|
|
|
13,781
|
|
Other income (expense),
net:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized net (loss)
gain on warrants
|
|
|
(162)
|
|
|
|
1,788
|
|
|
|
(745)
|
|
|
|
623
|
|
Unrealized net gain
(loss) on equity securities
|
|
|
—
|
|
|
|
13
|
|
|
|
—
|
|
|
|
(534)
|
|
(Loss) gain on foreign
currency transactions
|
|
|
(76)
|
|
|
|
—
|
|
|
|
426
|
|
|
|
—
|
|
Income before income
tax (benefit) expense
|
|
|
4,088
|
|
|
|
8,558
|
|
|
|
14,002
|
|
|
|
13,870
|
|
Income tax (benefit)
expense
|
|
|
(386)
|
|
|
|
1,942
|
|
|
|
959
|
|
|
|
3,211
|
|
Net income
|
|
$
|
4,474
|
|
|
$
|
6,616
|
|
|
$
|
13,043
|
|
|
$
|
10,659
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.36
|
|
|
$
|
0.52
|
|
|
$
|
1.03
|
|
|
$
|
0.83
|
|
Diluted
|
|
$
|
0.36
|
|
|
$
|
0.51
|
|
|
$
|
1.02
|
|
|
$
|
0.83
|
|
Weighted average shares
outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
12,539
|
|
|
|
12,832
|
|
|
|
12,703
|
|
|
|
12,832
|
|
Diluted
|
|
|
12,582
|
|
|
|
12,851
|
|
|
|
12,746
|
|
|
|
12,871
|
|
SWK HOLDINGS
CORPORATION
|
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(in
thousands)
|
|
|
|
Nine Months
Ended
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
13,043
|
|
|
$
|
10,659
|
|
Adjustments to
reconcile net income to net cash provided by operating
activities:
|
|
|
|
|
|
|
|
|
Benefit from credit
losses
|
|
|
(459)
|
|
|
|
—
|
|
Right-of-use asset
amortization
|
|
|
244
|
|
|
|
171
|
|
Amortization of debt
issuance costs
|
|
|
243
|
|
|
|
26
|
|
Deferred income
taxes
|
|
|
915
|
|
|
|
3,189
|
|
Change in fair value of
warrants
|
|
|
745
|
|
|
|
(623)
|
|
Change in fair value of
equity securities
|
|
|
—
|
|
|
|
534
|
|
Foreign currency
transaction gain
|
|
|
(375)
|
|
|
|
—
|
|
Loan discount and fee
accretion
|
|
|
(2,959)
|
|
|
|
(1,357)
|
|
Interest
paid-in-kind
|
|
|
(1,826)
|
|
|
|
(3,335)
|
|
Stock-based
compensation
|
|
|
369
|
|
|
|
310
|
|
Depreciation and
amortization expense
|
|
|
1,937
|
|
|
|
1,964
|
|
Changes in operating
assets and liabilities:
|
|
|
|
|
|
|
|
|
Interest and accounts
receivable
|
|
|
(1,317)
|
|
|
|
(5,581)
|
|
Other assets
|
|
|
(738)
|
|
|
|
(76)
|
|
Accounts payable and
other liabilities
|
|
|
(635)
|
|
|
|
(603)
|
|
Net cash provided by
operating activities
|
|
|
9,187
|
|
|
|
5,278
|
|
|
|
|
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
|
Proceeds from sale of
investments
|
|
|
13,942
|
|
|
|
—
|
|
Investment in finance
receivables
|
|
|
(17,525)
|
|
|
|
(71,750)
|
|
Repayment of finance
receivables
|
|
|
7,430
|
|
|
|
43,938
|
|
Corporate debt
securities principal payments
|
|
|
26
|
|
|
|
31
|
|
Purchases of property
and equipment
|
|
|
(299)
|
|
|
|
(194)
|
|
Net cash provided by
(used in) investing activities
|
|
|
3,574
|
|
|
|
(27,975)
|
|
|
|
|
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
|
Payments for financing
costs
|
|
|
(1,345)
|
|
|
|
—
|
|
Proceeds from (payments
on) credit facilities
|
|
|
19,555
|
|
|
|
(8)
|
|
Net settlement for
employee taxes on restricted stock and options
|
|
|
—
|
|
|
|
(160)
|
|
Repurchases of common
stock, including fees and expenses
|
|
|
(6,093)
|
|
|
|
(599)
|
|
Net cash provided by
(used in) financing activities
|
|
|
12,117
|
|
|
|
(767)
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease)
in cash and cash equivalents
|
|
|
24,878
|
|
|
|
(23,464)
|
|
Cash and cash
equivalents at beginning of period
|
|
|
6,156
|
|
|
|
42,863
|
|
Cash and cash
equivalents at end of period
|
|
$
|
31,034
|
|
|
$
|
19,399
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/swk-holdings-corporation-announces-financial-results-for-third-quarter-2023-301982880.html
SOURCE SWK Holdings Corporation